Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and areas of unmet medical need, has a portfolio of products aimed at treating orphan diseases. The United States (U.S.) Food and Drug Administration (FDA) defines an orphan disease as a rare disease or condition that affects fewer than 200,000 people in the U.S.. By focusing primarily on rare diseases, Soligenix can address the needs of niche but critical markets while having a long-lasting impact on patients’ outcomes and quality of life.
00:00With rare diseases on the rise, the demand for next-generation pharmaceutical solutions has never been greater.
00:07Soligenics, a late-stage biopharmaceutical company, is making significant strides with an innovative dual focus on specialized biotherapeutics and public health solutions.
00:16This dual strategy spans treatments for orphan conditions, such as cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Bessett's disease,
00:26as well as medical countermeasures against emerging threats like ricin toxin, pseudantipolavirus, and other viruses.
00:33Among Soligenics' diverse pipeline, Hybrite is at the forefront for the treatment of CTCL, a chronic skin cancer.
00:40It's a cutting-edge photodynamic therapy, harnessing synthetic hypericin, which is applied topically to the cancerous lesions and then activated by safe, visible light.
Be the first to comment